HOTH News and Press, Hoth Therapeutics Inc. From 06/26/22

3 Tips for Buying Penny Stocks in July If you’re thinking about buying penny stocks in 2022, there is a lot to know. As traders, it is our job to find the best penny stocks to buy and study them. We need to understand current trends, global market conditions that may effect t...

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis PR Newswire NEW YORK , June 21, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopha...

Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022 PR Newswire NEW YORK , June 15, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its An...

Hoth Therapeutics (NASDAQ:HOTH) on Thursday said it had entered into an extension of its research agreement with the Washington University in St. Louis, Mo. for the continued R&D of Hoth's HT-ALZ, a therapeutic for the treatment of Alzheimer's disease. HOTH stock -3.9% to $0.42 ...

Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ PR Newswire The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW ...

Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort PR Newswire The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severi...

Hoth Therapeutics (NASDAQ:HOTH) said it is adding a new asset to its pipeline, HT-TBI. The company said HT-TBI is being developed as a point-of-care therapy for treating secondary brain injury (such as brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury (TB...

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury PR Newswire HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and ...

Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire NEW YORK , April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today an...

Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...